AbbVie’s Final Phase 3 MIRASOL Data Confirms 32% Reduced Risk of Death with ELAHERE in Platinum-Resistant Ovarian Cancer

Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with E...

March 17, 2025 | Monday | News
SLIM LIVER Study Identifies Epigenetic Biomarkers for Semaglutide Response in HIV-Related Liver Disease

ACTG, a global clinical trials network focused on HIV and other infectious diseases, announced new findings from the SLIM LIVER study (also known as A5371)...

March 11, 2025 | Tuesday | News
Roche Opens Genentech Innovation Center in Boston, Expands Harvard R&D and AI Collaboration

Roche  announced  the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston which will ...

March 10, 2025 | Monday | News
FibroBiologics Files Patent for Innovative Approach to Enhance Mitochondrial Performance Using Fibroblasts

FibroBiologics, Inc. a clinical-stage biotechnology company with over 160 issued and pending patents focused on the development of therapeutics and potenti...

March 05, 2025 | Wednesday | News
Celldex Reports Positive Phase 2 Results for Barzolvolimab in Chronic Urticaria

Celldex Therapeutics, Inc. announced  positive data on measurements of disease control and quality of life from the Company’s Phase 2 barzolvoli...

March 03, 2025 | Monday | News
GSK Announces Positive Phase III Results for Depemokimab in Treating Chronic Rhinosinusitis with Nasal Polyps

GSK plc announced full results from the positive ANCHOR-1 and ANCHOR-2 phase III clinical trials assessing the efficacy and safety of depemokimab versus pl...

March 03, 2025 | Monday | News
Roche Group Unveils Promising Results from NIH-Sponsored OUtMATCH Study, Highlighting Xolair® as a Leading Treatment for Food Allergies

Roche Group announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored Phase III OUtMATCH study, which provi...

March 03, 2025 | Monday | News
Alumis to Present Data on A-005, a Novel TYK2 Inhibitor, at ACTRIMS Forum 2025

Alumis Inc. (“Alumis” or the “Company”), a clinical stage biopharmaceutical company developing oral therapies using a precision app...

February 28, 2025 | Friday | News
Alamar Biosciences Launches NULISAqpcr™ Custom Assay Development Kit for Advanced Biomarker Research

Alamar Biosciences, a company that is building the power of high-precision proteomics for early disease detection, is proud to announce the launch of the N...

February 26, 2025 | Wednesday | News
Harvard Bioscience to Showcase Cutting-Edge Innovations at 2025 Society of Toxicology Conference

Harvard Bioscience, Inc. will present its latest product innovations at the Society of Toxicology (SOT) conference, further advancing preclinical research ...

February 25, 2025 | Tuesday | News
FDA Approves Ctexli (Chenodiol) as the First Treatment for Cerebrotendinous Xanthomatosis (CTX) in Adults

The U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is ...

February 24, 2025 | Monday | News
Merilog Receives FDA Approval as the First Rapid-Acting Insulin Biosimilar

The U.S. Food and Drug Administration (FDA) approved Merilog (insulin aspart szij) as a Novolog biosimilar to (insulin aspart) to improve glycemi...

February 20, 2025 | Thursday | News
3Z Pharmaceuticals Unveils Groundbreaking Study Supporting Amlodipine as a Novel Non-Stimulant ADHD Therapy

3Z Pharmaceuticals announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positio...

February 18, 2025 | Tuesday | News
Navi Medical Technologies' Neonav® ECG Tip Location System Receives FDA 510(k) Clearance for Pediatric Care

Navi Medical Technologies, a medical device company focused on pediatric healthcare innovation, proudly announces that its Neonav® ECG Tip Location Sys...

February 18, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close